Stock Expert AI
USAQ company logo

QHSLab, Inc. (USAQ) — AI Hisse Senedi Analizi

QHSLab, Inc. operates in the healthcare sector, focusing on medical device technology and SaaS solutions. The company develops digital therapeutics and point-of-care solutions, offering a cloud-based system for healthcare organizations.

Şirket Genel Bakışı

ÇOK UZUN; OKUMADIM:

QHSLab, Inc. operates in the healthcare sector, focusing on medical device technology and SaaS solutions. The company develops digital therapeutics and point-of-care solutions, offering a cloud-based system for healthcare organizations.
QHSLab, Inc. is a healthcare technology company specializing in value-based healthcare solutions, including SaaS platforms and medical devices. The company's focus on algorithmic personalized medicine and remote patient monitoring positions it within the evolving digital health landscape, serving physicians and healthcare organizations with tools for chronic disease management and prevention.

USAQ Hakkında

QHSLab, Inc., formerly known as USA Equities Corp., was incorporated in 1983 and rebranded in April 2022 to reflect its focus on healthcare technology. Based in West Palm Beach, Florida, the company operates as a medical device technology and software as a service (SaaS) provider, targeting value-based healthcare. QHSLab develops digital therapeutics and point-of-care solutions designed to support remote patient monitoring, chronic care management, and preventive medicine. The company's key product is the Quality Health Score Lab Expert System (QHSLab), a cloud-based SaaS platform that enables physicians and healthcare organizations to electronically capture and securely store patient information. This system aims to improve data management and accessibility for healthcare providers. Additionally, QHSLab distributes AllergiEnd, a diagnostic product, and allergen immunotherapy treatments to primary care physicians. QHSLab's products are designed to promote the prevention, early detection, management, and potential reversal of chronic diseases. The company has a strategic alliance with Medical License Factory, LLC, to expand its reach and service offerings within the healthcare sector. With a small team of four employees, QHSLab is focused on leveraging technology to improve healthcare outcomes and efficiency.

Yatırım Tezi

QHSLab, Inc. presents a focused investment opportunity within the digital health space, targeting chronic disease management and remote patient monitoring. With a market capitalization of $0.01 billion and a negative P/E ratio of -19.31, the company is currently not profitable, but its gross margin of 66.4% indicates potential for future profitability. Key to the investment thesis is the successful adoption and scaling of its QHSLab SaaS platform and AllergiEnd product line. Ongoing: The company's strategic alliance with Medical License Factory, LLC could drive growth through expanded market access and service offerings. Potential: Achieving profitability and demonstrating sustained revenue growth will be critical for long-term value creation.

Sektör Bağlamı

QHSLab, Inc. operates within the rapidly evolving digital health market, which is experiencing significant growth driven by increasing adoption of telehealth, remote patient monitoring, and personalized medicine. The industry is characterized by intense competition, with established players and emerging startups vying for market share. QHSLab's focus on value-based healthcare and chronic disease management aligns with key industry trends. The company competes with other medical device and SaaS providers, including AGNPF (Agenus Inc.), APLIF (Applied LifeSciences Inc.), CSOC (Custom Solutions Oncology), CVGRF (Cervus Corp), and GENPF (Genpharm Inc.).
Medical - Devices
Healthcare

Büyüme Fırsatları

  • Expansion of QHSLab SaaS Platform: QHSLab can expand its market share by increasing the adoption of its QHSLab SaaS platform among physicians and healthcare organizations. The market for healthcare SaaS solutions is projected to reach $45 billion by 2028, driven by the need for efficient data management and improved patient care. Timeline: Ongoing, with continuous updates and marketing efforts to attract new clients. Competitive advantage: The platform's focus on chronic disease management and personalized medicine.
  • Strategic Partnerships and Alliances: QHSLab can leverage strategic partnerships to expand its reach and service offerings. Collaborating with other healthcare providers, technology companies, and research institutions can provide access to new markets and technologies. Timeline: Ongoing, with continuous exploration of potential partnerships. Competitive advantage: Leveraging existing alliance with Medical License Factory, LLC.
  • Development of New Digital Therapeutics: QHSLab can invest in the development of new digital therapeutics to address unmet needs in chronic disease management. The market for digital therapeutics is expected to reach $9.6 billion by 2025, driven by the increasing prevalence of chronic diseases and the demand for personalized treatment options. Timeline: 2-3 years for development and regulatory approval. Competitive advantage: Focus on algorithmic personalized medicine.
  • Geographic Expansion: QHSLab can expand its operations to new geographic markets, both domestically and internationally. The global market for healthcare technology is growing rapidly, particularly in emerging economies. Timeline: 1-2 years for market entry and regulatory compliance. Competitive advantage: Scalable SaaS platform and remote patient monitoring solutions.
  • Integration of AI and Machine Learning: QHSLab can integrate artificial intelligence (AI) and machine learning (ML) technologies into its products and services to improve diagnostic accuracy, personalize treatment plans, and automate administrative tasks. The market for AI in healthcare is projected to reach $34 billion by 2027, driven by the increasing availability of data and the demand for intelligent healthcare solutions. Timeline: 1-2 years for development and integration. Competitive advantage: Focus on algorithmic personalized medicine.
  • Market capitalization of $0.01 billion reflects its current valuation in the OTC market.
  • Negative P/E ratio of -19.31 indicates the company is not currently profitable.
  • Gross margin of 66.4% suggests strong potential for profitability with increased sales and cost management.
  • Beta of 0.58 indicates lower volatility compared to the broader market.
  • Strategic alliance with Medical License Factory, LLC, aims to expand market reach and service offerings.

Ne Yaparlar

  • Develops medical device technology for value-based healthcare.
  • Offers a cloud-based SaaS system (QHSLab) for electronic patient information management.
  • Provides digital therapeutics and point-of-care solutions.
  • Supports remote patient monitoring for chronic care and preventive medicine.
  • Distributes AllergiEnd, a diagnostic product and allergen immunotherapy treatments.
  • Focuses on prevention, early detection, and management of chronic diseases.

İş Modeli

  • Sells subscriptions to its QHSLab SaaS platform to physicians and healthcare organizations.
  • Distributes AllergiEnd and allergen immunotherapy treatments to primary care physicians.
  • Generates revenue through strategic alliances and partnerships.
  • Develops and commercializes digital therapeutics.
  • Primary care physicians
  • Healthcare organizations
  • Patients with chronic diseases
  • Individuals seeking preventive care
  • Proprietary QHSLab SaaS platform for electronic patient information management.
  • Strategic alliance with Medical License Factory, LLC.
  • Focus on algorithmic personalized medicine.
  • Distribution network for AllergiEnd and allergen immunotherapy treatments.

Katalizörler

  • Upcoming: Potential FDA approval for new digital therapeutics.
  • Ongoing: Expansion of the QHSLab SaaS platform to new healthcare organizations.
  • Ongoing: Strategic alliance with Medical License Factory, LLC driving market reach.
  • Upcoming: Positive clinical trial results for AllergiEnd product.
  • Ongoing: Increasing adoption of remote patient monitoring solutions.

Riskler

  • Potential: Intense competition in the healthcare technology market.
  • Potential: Regulatory changes and compliance requirements.
  • Potential: Cybersecurity risks and data breaches.
  • Ongoing: Limited financial resources and lack of profitability.
  • Ongoing: OTC market listing with associated risks.

Güçlü Yönler

  • Proprietary QHSLab SaaS platform.
  • Strategic alliance with Medical License Factory, LLC.
  • Focus on value-based healthcare and personalized medicine.
  • Distribution of AllergiEnd product.

Zayıflıklar

  • Small company with limited resources (4 employees).
  • Negative P/E ratio indicating lack of profitability.
  • OTC market listing with associated risks.
  • Limited brand recognition.

Fırsatlar

  • Expansion of QHSLab SaaS platform to new markets.
  • Development of new digital therapeutics.
  • Strategic partnerships and acquisitions.
  • Increased adoption of remote patient monitoring.

Tehditler

  • Intense competition in the healthcare technology market.
  • Regulatory changes and compliance requirements.
  • Cybersecurity risks and data breaches.
  • Economic downturn and reduced healthcare spending.

Rakipler & Benzerleri

  • Agenus Inc. — Focuses on immuno-oncology products. — (AGNPF)
  • Applied LifeSciences Inc. — Develops innovative drug delivery systems. — (APLIF)
  • Custom Solutions Oncology — Provides personalized cancer treatment solutions. — (CSOC)
  • Cervus Corp — Develops innovative health and wellness products. — (CVGRF)
  • Genpharm Inc. — Specializes in generic pharmaceutical products. — (GENPF)

Key Metrics

  • Volume: 0
  • MoonshotScore: 62/100

Company Profile

  • CEO: Troy James Grogan
  • Headquarters: West Palm Beach, US
  • Employees: 4
  • Founded: 2013

AI Insight

AI analysis pending for USAQ
  • OTC Tier: OTC Other
  • Disclosure Status: Unknown

Sorular & Cevaplar

What does QHSLab, Inc. do?

QHSLab, Inc. is a healthcare technology company that develops and markets medical devices and SaaS solutions. Its primary focus is on value-based healthcare, informatics, and algorithmic personalized medicine. The company provides digital therapeutics and point-of-care solutions to support remote patient monitoring, chronic care, and preventive medicine. QHSLab's key product is the QHSLab SaaS platform, which enables physicians and healthcare organizations to manage patient information electronically. Additionally, the company distributes AllergiEnd, a diagnostic product and allergen immunotherapy treatments.

What do analysts say about USAQ stock?

As of March 17, 2026, there is no readily available analyst coverage for USAQ stock due to its listing on the OTC Other market and its small market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include a market cap of $0.01 billion and a negative P/E ratio of -19.31. Growth considerations include the successful adoption of its QHSLab SaaS platform and the expansion of its product offerings.

What are the main risks for USAQ?

The main risks for QHSLab, Inc. include intense competition in the healthcare technology market, regulatory changes and compliance requirements, cybersecurity risks and data breaches, limited financial resources and lack of profitability, and the risks associated with its OTC market listing. The company's small size and limited brand recognition may also pose challenges to its growth prospects. Investors should carefully consider these risks before investing in USAQ stock.

How does QHSLab, Inc. navigate regulatory approval processes?

QHSLab, Inc. navigates regulatory approval processes by ensuring compliance with relevant regulations and standards for medical devices and software as a service (SaaS) solutions. The company works closely with regulatory agencies to obtain necessary approvals for its products, including digital therapeutics and diagnostic products. QHSLab's regulatory strategy involves maintaining a strong focus on quality control, data privacy, and patient safety. The company's track record in obtaining regulatory approvals is not publicly available.

What are the key growth opportunities for USAQ in healthcare?

Key growth opportunities for QHSLab, Inc. in healthcare include expanding the adoption of its QHSLab SaaS platform among physicians and healthcare organizations, developing new digital therapeutics to address unmet needs in chronic disease management, leveraging strategic partnerships to expand its reach and service offerings, expanding its operations to new geographic markets, and integrating artificial intelligence (AI) and machine learning (ML) technologies into its products and services. These opportunities align with key industry trends and the increasing demand for personalized and technology-driven healthcare solutions.

Is USAQ a good investment right now?

Use the AI score and analyst targets on this page to evaluate QHSLab, Inc. (USAQ). Our analysis considers fundamentals, technicals, and market sentiment to help you decide.

What is the MoonshotScore for USAQ?

The MoonshotScore is a proprietary 0-100 AI rating that evaluates QHSLab, Inc. across multiple dimensions including financial health, growth trajectory, and risk factors.

Where can I find USAQ financial statements?

QHSLab, Inc. financial data including revenue, earnings, and balance sheet metrics are available in the Financials tab on this page, sourced from institutional-grade data providers.